Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 17,498,000	$ 22,527,000
General and administrative	11,659,000	12,113,000
Operating loss	(29,157,000)	(34,640,000)
Other income (expense), net:
Interest expense	(1,449,000)	(1,618,000)
Interest income and other income (expense), net	1,115,000	549,000
Other income (expense), net	(334,000)	(1,069,000)
Provision for income taxes	0	0
Net loss	$ (29,491,000)	$ (35,709,000)
Net loss per share of common stock and pre-funded warrants, basic	$ (1.91)	$ (3.09)
Net loss per share of common stock and pre-funded warrants, diluted	$ (1.91)	$ (3.09)
Weighted-average shares of common stock and pre-funded warrants outstanding, basic	15,416,203	11,548,907
Weighted-average shares of common stock and pre-funded warrants outstanding, diluted	15,416,203	11,548,907